Control of viral rebound through therapeutic immunization with DermaVir

Julianna Lisziewicz, Jeffrey Trocio, Jianqing Xu, Lucia Whitman, Amy Ryder, Nyasha Bakare, Mark G. Lewis, Wendeline Wagner, Angela Pistorio, Suresh Arya, Franco Lori

Research output: Contribution to journalArticlepeer-review


Objective: To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection. Design: A topical, DNA-based therapeutic immunization (DermaVir) was designed to express most of the regulatory and structural viral genes in dendritic cells. Methods: DermaVir alone and in combination with antiretroviral drugs was tested in chronically SIV-infected macaques. Results: DermaVir provided virological, immunological and clinical benefit for SIV-infected macaques during chronic infection and AIDS. In combination with antiretroviral drugs, DermaVir augmented SIV-specific T-cell responses and enhanced control of viral load rebound during treatment interruptions. Conclusions: The results indicate the feasibility of therapeutic immunization even in immune compromised hosts, and suggest that DermaVir can complement antiretroviral drugs to sustain suppression of HIV-1 replication.

Original languageEnglish
Pages (from-to)35-43
Number of pages9
JournalAIDS (London, England)
Issue number1
Publication statusPublished - Jan 3 2005


  • Dendritic cells
  • HIV therapy
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Control of viral rebound through therapeutic immunization with DermaVir'. Together they form a unique fingerprint.

Cite this